Skip to main content
Traws Pharma, Inc. logo

Traws Pharma, Inc. — Investor Relations & Filings

Ticker · TRAW ISIN · US68232V8845 LEI · 549300BRAR7BTG2PIY51 US Manufacturing
Filings indexed 927 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country US United States of America
Listing US TRAW

About Traws Pharma, Inc.

https://www.trawspharma.com/

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel oral small-molecule therapies for respiratory viral diseases. The company focuses on advancing investigational antiviral agents with potent activity against difficult-to-treat or resistant virus strains. Its pipeline includes two lead candidates: ratutrelvir, a ritonavir-independent antiviral targeting the Main protease (Mpro) for the treatment of COVID-19 and Long COVID, and tivoxavir marboxil, a single-dose antiviral targeting the influenza cap-dependent endonuclease (CEN) for the treatment and prevention of bird flu and seasonal influenza. The company aims to develop safe product candidates with simple dosing regimens.

Recent filings

Filing Released Lang Actions
424B5
Regulatory Filings
2026-05-22 English
424B3
Regulatory Filings
2026-05-15 English
10-Q
Interim / Quarterly Report
2026-05-15 English
FORM 8-K
Regulatory Filings
2026-05-15 English
S-3 - Traws Pharma, Inc. (0001130598) (Filer)
Regulatory Filings
2026-05-08 English
10-K - Traws Pharma, Inc. (0001130598) (Filer)
Annual Report FY 2025
2026-04-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.